Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
MTBC is a healthcare information technology company that provides a fully integrat...
MTBC is a healthcare information technology com...
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic a...
Lipocine Inc. is a clinical-stage biopharmaceut...
We are a clinical-stage biopharmaceutical company committed to realizing the promi...
We are a clinical-stage biopharmaceutical compa...
Vaxart is focused on developing oral recombinant protein vaccines administered usi...
Vaxart is focused on developing oral recombinan...
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developi...
Urovant Sciences is a clinical-stage biopharmac...
Akorn, Inc. is a niche pharmaceutical company that develops, manufactures and mark...
Akorn, Inc. is a niche pharmaceutical company t...
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on th...
G1 Therapeutics, Inc., is a clinical-stage biop...
Join the National Investor Network and get the latest information with your interests in mind.